Loading...
Founded in 2018
We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.
Founded
2018
Employees
Funding
Eric Boutin
Investor
Francis Ho
Board Observer